Drugs / Teslanbai
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06974123 | Oct 2024 → Dec 2026 expected | — | The First Affiliated Hospital of Xinxiang Medical College | Enrolling by invitation | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Teslanbai | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06974123 ↗ |
| Known as | Teslanbai bacteria | “Teslanbai bacteria, a novel probiotic derived from Lactobacillus rhamnosus (strain CICC 6137 from China Center of Industrial Culture Collection), incorporates nano-selenium via...” NCT06974123 ↗ |
| Modality | Other / unclassified | “Teslanbai bacteria, a novel probiotic derived from Lactobacillus rhamnosus” NCT06974123 ↗ |
| Route | Oral | “will receive oral administration” NCT06974123 ↗ |